B. Riley started coverage on shares of AVEO Pharmaceuticals (NASDAQ:AVEO) in a report released on Tuesday, The Fly reports. The brokerage issued a buy rating and a $5.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently weighed in on AVEO. Robert W. Baird began coverage on shares of AVEO Pharmaceuticals in a research report on Thursday, January 3rd. They set an outperform rating and a $3.00 price objective for the company. FBR & Co set a $3.00 price target on shares of AVEO Pharmaceuticals and gave the company a buy rating in a research report on Thursday, December 20th. National Securities cut shares of AVEO Pharmaceuticals from a buy rating to a neutral rating in a research report on Tuesday, November 6th. Zacks Investment Research cut shares of AVEO Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, October 23rd. Finally, HC Wainwright set a $9.00 price target on shares of AVEO Pharmaceuticals and gave the company a buy rating in a research report on Thursday, December 13th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $4.45.

Shares of NASDAQ:AVEO traded down $0.07 during mid-day trading on Tuesday, reaching $1.99. 427,306 shares of the company were exchanged, compared to its average volume of 1,486,286. The stock has a market capitalization of $265.73 million, a P/E ratio of -12.44 and a beta of 2.14. AVEO Pharmaceuticals has a 1 year low of $1.40 and a 1 year high of $3.59.

AVEO Pharmaceuticals (NASDAQ:AVEO) last posted its quarterly earnings data on Friday, November 9th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.01. The company had revenue of $2.47 million for the quarter, compared to analysts’ expectations of $0.68 million. On average, equities analysts predict that AVEO Pharmaceuticals will post -0.25 earnings per share for the current year.

In other news, major shareholder Peter J. Barris acquired 500,000 shares of AVEO Pharmaceuticals stock in a transaction dated Friday, December 21st. The shares were acquired at an average cost of $1.55 per share, for a total transaction of $775,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Anthony B. Evnin sold 325,139 shares of the firm’s stock in a transaction on Wednesday, November 14th. The shares were sold at an average price of $1.90, for a total transaction of $617,764.10. The disclosure for this sale can be found here. Insiders acquired a total of 2,358,709 shares of company stock valued at $4,272,673 in the last three months. 4.40% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. NEA Management Company LLC raised its holdings in shares of AVEO Pharmaceuticals by 5.1% in the 3rd quarter. NEA Management Company LLC now owns 18,698,038 shares of the biopharmaceutical company’s stock valued at $61,891,000 after purchasing an additional 914,316 shares in the last quarter. BlackRock Inc. raised its holdings in shares of AVEO Pharmaceuticals by 2.1% in the 3rd quarter. BlackRock Inc. now owns 7,120,894 shares of the biopharmaceutical company’s stock valued at $23,570,000 after purchasing an additional 143,148 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of AVEO Pharmaceuticals by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,066,360 shares of the biopharmaceutical company’s stock valued at $16,770,000 after purchasing an additional 73,519 shares in the last quarter. Vanguard Group Inc raised its holdings in shares of AVEO Pharmaceuticals by 1.5% in the 3rd quarter. Vanguard Group Inc now owns 5,066,360 shares of the biopharmaceutical company’s stock valued at $16,770,000 after purchasing an additional 73,519 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of AVEO Pharmaceuticals by 396.0% in the 2nd quarter. Northern Trust Corp now owns 1,098,075 shares of the biopharmaceutical company’s stock valued at $2,482,000 after purchasing an additional 876,703 shares in the last quarter. Institutional investors and hedge funds own 40.11% of the company’s stock.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Featured Story: What is a good rate of return for a mutual fund?

The Fly

Analyst Recommendations for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.